James Tobin - Globus Medical Independent Director
| GMED Stock | USD 73.91 0.57 0.78% |
Director
Mr. James R. Tobin serves as Independent Director of the Company. Mr. Tobin served as President and Chief Executive Officer of Boston Scientific from March 1999 to July 2009. Before joining Boston Scientific, Mr. Tobin served Biogen, Inc. as its President and CEO from 1997 to 1998 and as its Chief Operating Officer from 1994 to 1997. Mr. Tobin served Baxter International in various capacities from 1972 to 1994, including as its President and Chief Operating Officer from 1992 to 1994. Mr. Tobin also currently serves on the board of directors of Oxford Immunotec Global PLC, a global diagnostics company, Corindus Vascular Robotics, Inc., a leading developer of precision vascular robotics, and two private companies, TransMedics, Inc. and Resolys Bio, Inc. He served as Lieutenant in the U.S. Navy from 1968 to 1972 since 2015.
| Age | 75 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Address | 2560 General Armistead Avenue, Audubon, PA, United States, 19403 |
| Phone | 610 930 1800 |
| Web | https://www.globusmedical.com |
James Tobin Latest Insider Activity
Tracking and analyzing the buying and selling activities of James Tobin against Globus Medical stock is an integral part of due diligence when investing in Globus Medical. James Tobin insider activity provides valuable insight into whether Globus Medical is net buyers or sellers over its current business cycle. Note, Globus Medical insiders must abide by specific rules, including filing SEC forms every time they buy or sell Globus Medical'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
James Tobin over six months ago Acquisition by James Tobin of 3000 shares of Neogen at 15.189 subject to Rule 16b-3 | ||
James Tobin over a year ago Acquisition by James Tobin of 15000 shares of Globus Medical subject to Rule 16b-3 | ||
James Tobin over a year ago Exercise or conversion by James Tobin of 13716 shares of Neogen subject to Rule 16b-3 | ||
James Tobin over a year ago Acquisition by James Tobin of 15000 shares of Globus Medical subject to Rule 16b-3 |
Globus Medical Management Efficiency
The company has return on total asset (ROA) of 0.0533 % which means that it generated a profit of $0.0533 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0252 %, meaning that it created $0.0252 on every $100 dollars invested by stockholders. Globus Medical's management efficiency ratios could be used to measure how well Globus Medical manages its routine affairs as well as how well it operates its assets and liabilities. As of March 21, 2025, Return On Tangible Assets is expected to decline to 0.03. In addition to that, Return On Capital Employed is expected to decline to 0.04. At present, Globus Medical's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 148.3 M, whereas Return On Tangible Assets are forecasted to decline to 0.03.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Jerome Lande | CONMED | 45 | |
| David Hoffmeister | Glaukos Corp | 66 | |
| Brian Concannon | CONMED | 62 | |
| John Workman | CONMED | 69 | |
| Alvin Jeffers | Integer Holdings Corp | 47 | |
| Brad Vale | Nevro Corp | 67 | |
| Casey Tansey | Inspire Medical Systems | 63 | |
| Shawn McCormick | Inspire Medical Systems | 56 | |
| Frank Fischer | Nevro Corp | 78 | |
| Kristen CFA | Integer Holdings Corp | N/A | |
| Jerry Griffin | Inspire Medical Systems | 76 | |
| Pamela Bailey | Integer Holdings Corp | 72 | |
| David Bronson | CONMED | 67 | |
| Mark Foley | Glaukos Corp | 55 | |
| Martha Aronson | CONMED | 53 | |
| Elizabeth Weatherman | Nevro Corp | 60 | |
| Susan Siegel | Nevro Corp | 60 | |
| Gilbert Kliman | Glaukos Corp | 61 | |
| Shawn McCormick | Nevro Corp | 56 | |
| Megan CPA | Inspire Medical Systems | N/A | |
| Marc Stapley | Glaukos Corp | 50 | |
Management Performance
| Return On Equity | 0.0252 | ||||
| Return On Asset | 0.0533 |
Globus Medical Leadership Team
Elected by the shareholders, the Globus Medical's board of directors comprises two types of representatives: Globus Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Globus. The board's role is to monitor Globus Medical's management team and ensure that shareholders' interests are well served. Globus Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Globus Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steve Zarrilli, Independent Director | ||
| David Paul, Co-Founder, Chairman, CEO, Chairman of Compensation Committee and Chairman of Nominating and Corporate Governance Committee | ||
| Mike Reeder, Ex Officer | ||
| Ann Rhoads, Independent Director | ||
| Robert Douglas, Independent Director | ||
| Steven Payne, VP Controller | ||
| Kelly Esq, Executive Counsel | ||
| Kelly Huller, Senior Vice President General Counsel, Corporate Secretary | ||
| Stephen Zarrilli, Independent Director | ||
| James Tobin, Independent Director | ||
| Brian Kearns, Senior Relations | ||
| Brett Murphy, Group President of Commercial Operations | ||
| Richard Holifield, Ex Officer | ||
| Daniel Lemaitre, Independent Director | ||
| John Dowling, Ex Officer | ||
| Keith Pfeil, Chief Financial Officer, Senior Vice President | ||
| David Demski, Group President of Emerging Technologies, Director and Member of Nominating and Corporate Governance Committee | ||
| Daniel Scavilla, Executive Vice President, Chief Commercial Officer and President - Trauma | ||
| David Davidar, Co-Founder, Sr. VP of Operations and Director |
Globus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Globus Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0252 | ||||
| Return On Asset | 0.0533 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.19 % | ||||
| Current Valuation | 9.73 B | ||||
| Shares Outstanding | 115.11 M | ||||
| Shares Owned By Insiders | 0.62 % | ||||
| Shares Owned By Institutions | 81.84 % | ||||
| Number Of Shares Shorted | 2.62 M | ||||
| Price To Earning | 73.16 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Globus Medical is a strong investment it is important to analyze Globus Medical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Globus Medical's future performance. For an informed investment choice regarding Globus Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Globus Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For information on how to trade Globus Stock refer to our How to Trade Globus Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Globus Medical. If investors know Globus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Globus Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.827 | Earnings Share 0.75 | Revenue Per Share | Quarterly Revenue Growth 0.066 | Return On Assets |
The market value of Globus Medical is measured differently than its book value, which is the value of Globus that is recorded on the company's balance sheet. Investors also form their own opinion of Globus Medical's value that differs from its market value or its book value, called intrinsic value, which is Globus Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Globus Medical's market value can be influenced by many factors that don't directly affect Globus Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Globus Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Globus Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Globus Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.